Abstract:Background: Multiparametric magnetic resonance imaging (MRI) combined with prostate-specific-antigen density (PSAd) enhances the detection of significant prostate cancer (sPCa). However, it is unclear whether simple biparametric (bp) MRI, which reduces scan sequences, time, and cost, may be an equally effective noninvasive tool for detecting and ruling out sPCa and avoiding biopsies in biopsy-naïve men. Objective: To assess the diagnostic accuracy, predictive values, and best biopsy strategy combining bpMRI and PSAd in detecting and ruling out sPCa (Gleason score ≥7). Design, setting, and participants: Assessment of 808 biopsy-naïve men with clinical suspicion of localised PCa (prostate-specific antigen <20ng/ml, rectal examination <cT3), prospectively enrolled between November 2015 and June 2017. Intervention: All men underwent upfront bpMRI (T2- and diffusion-weighted imaging) followed by standard and targeted biopsies of any suspicious bpMRI findings. Outcome measurements and statistical analysis: Various bpMRI scores and PSAd thresholds were assessed using sPCa detection rates, predictive values, and proportion of biopsies avoided. Net benefits and decision curve analyses were compared. Combined biopsies from all men were used for reference. Results and limitations: Significant prostate cancers were detected in 283/808 (35%) men with median age and PSA (interquartile range) of 65 yr (60-70) and 6.9ng/ml (5.4-9.5), respectively. PSAd significantly influenced the predictive values of bpMRI in detecting and ruling out sPCa. The best strategy was restricting biopsies to men with highly suspicious bpMRI findings (score ≥4) or PSAd ≥0.15ng/ml/cc. This reduced the number of men requiring biopsies by 41% (329/808) and overdiagnosis of insignificant cancers by 45% (79/177), while missing only 5% (17/329) of men with sPCa. Study limitations included single-centre analysis and combined biopsies as the reference standard. Conclusions: Combination of bpMRI with PSAd improves diagnostic accuracy and predictive values for sPCa detection in biopsy-naïve men. Restricting biopsies to men with highly suspicious bpMRI findings (score ≥4) or PSAd ≥0.15ng/ml/cc was the best biopsy strategy in our patient cohort, effectively balancing risks and benefits. Studies are needed to validate our findings in other patient populations. Patient summary: This report shows that biopsy-naïve men with clinical suspicion of prostate cancer who have low- or equivocal-suspicion biparametric magnetic resonance imaging results and a low prostate-specific antigen density may not require immediate prostate biopsies.

Do we need MRI in all biopsy naïve patients? A multicenter cohort analysis

Biopsy strategies in the era of mpMRI: a comprehensive review

Are systematic prostate biopsy still necessary in biopsy naive men?

Avoiding Unnecessary Systematic Biopsy in Clinically Significant Prostate Cancer: Comparison Between MRI‐Based Radiomics Model and PI‐RADS Category

Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis

Magnetic resonance imaging-guided biopsies may improve diagnosis in biopsy-naive men with suspicion of prostate cancer

A Phase II Prospective Blinded Trial of Magnetic Resonance Imaging and In-Bore Biopsy in Active Surveillance for Prostate Cancer

Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men

Is Confirmatory Biopsy Still Necessary for Active Surveillance of Men With Grade Group 1 Prostate Cancer in the Era of Multiparametric MRI?

Assessment of diagnostic value of unilateral systematic biopsy combined with targeted biopsy in detecting clinically significant prostate cancer

Comparison of risk-calculator and MRI and consecutive pathways as upfront stratification for prostate biopsy

Accuracy of MRI-ultrasound fusion-guided and systematic biopsy of the prostate

Tailoring biopsy strategy in the MRI-fusion prostate biopsy era: systematic, targeted or neither?

Prostate cancer detection and complications of MRI-targeted prostate biopsy using cognitive registration, software-assisted image fusion or in-bore guidance: a systematic review and meta-analysis of comparative studies

Risk Calculator Strategy Before Magnetic Resonance Imaging Stratification for Biopsy-naïve Men with Suspicion for Prostate Cancer: A Cost-effectiveness Analysis

Prostate cancer detection rate with MRI-targeted biopsy alone using outpatient transperineal prostate biopsy

Combined MRI-TRUS fusion targeted and systematic biopsy versus systematic biopsy alone for the detection of prostate cancer: protocol for a prospective single-centre trial

Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI‐Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk‐Stratification Scoring System

Transition from Transrectal to Transperineal MRI-Fusion Prostate Biopsy Does Not Comprise Detection Rates of Clinically Significant Prostate Cancer at a Tertiary Care Center

MRI and Targeted Biopsy Essential Tools for an Accurate Diagnosis and Treatment Decision Making in Prostate Cancer

Effectiveness and Accuracy of MRI‐Ultrasound Fusion Targeted Biopsy Based on PI‐RADS v2.1 Category in Transition/Peripheral Zone of the Prostate